Dr. Chi Van Dang is CEO and scientific director of the Ludwig Institute for Cancer Research and Bloomberg Distringuished Professor of Cancer Medicine at Johns Hopkins University School of Medicine. His research helped define the complex functions of the MYC oncogene, a central switch in human cancer, identifying key domains that mediate its transcription factor activity. The Dang Lab also established the first mechanistic link between MYC and cellular energy metabolism, contributing to the concept that genetic alterations re-program energy utilization and render cancer cells addicted to certain energy sources. His Lab further documented that MYC could disrupt circadian metabolism and is exploiting these concepts for therapeutic targeting of cancer cell metabolism as a new anticancer strategy. He was the editor-in-chief of Cancer Research, a member of the National Academy of Medicine and fellow of the American Academy of Arts & Sciences and the American Association for Cancer Research Academy. He received his B.S. in chemistry from the University of Michigan and a Ph.D. in chemistry from Georgetown University, followed by an M.D. degree from the Johns Hopkins University School of Medicine. He is board-certified in Internal Medicine and Medical Oncology.